Cargando…

Liraglutide for non-alcoholic fatty liver disease in children and adolescents: has a new era arrived?

Detalles Bibliográficos
Autor principal:	Patoulias, Dimitrios Ioannis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2019
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6807668/ https://www.ncbi.nlm.nih.gov/pubmed/31649796 http://dx.doi.org/10.5114/pg.2019.88172

Ejemplares similares

Lean non-alcoholic fatty liver disease: do not forget diabetes
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease in patients with inflammatory bowel disease might boost cardiovascular disease burden
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated “enemy”?
por: Patoulias, Dimitrios, et al.
Publicado: (2020)

Empagliflozin promises to bridge the gap between non-alcoholic fatty liver disease, type 2 diabetes, and cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2018)

Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease
por: Patoulias, Dimitrios, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease, diabetes medications and blood pressure
por: Ilias, Ioannis, et al.
Publicado: (2021)

The Era of Telehealth Has Arrived
por: Stanton, Bonita F.
Publicado: (2020)

miRNA-122: Can it unravel an alternative pathway in early diagnosis and prognosis of type 2 diabetes mellitus?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Canakinumab: can it untie the Gordian knot of cardiovascular disease in patients with familial Mediterranean fever?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Is there a distinct phenotype of diabetic patients who benefit from tofogliflozin?
por: Patoulias, Dimitrios Ioannis
Publicado: (2018)

Sodium glucose co-transporter 2 inhibitors mediated ketogenesis in patients with metabolic syndrome: clear benefit or anticipated fear?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Sexual dysfunction among women with systemic lupus erythematosus: might it reflect cardiovascular disease burden?
por: Patoulias, Dimitrios Ioannis
Publicado: (2019)

Serum chemerin in patients with rheumatoid arthritis: can it unravel the Chimera of concomitant type 2 diabetes?
por: Patoulias, Dimitrios Ioannis
Publicado: (2020)

Non-diabetic use of liraglutide
por: Verma, Abhyudaya
Publicado: (2012)

Body Composition and Non-alcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2016)

Well-designed trials on TEE monitoring in the ICU: The time has arrived
por: Krishnamoorthy, Vijay
Publicado: (2014)

Eyeing non-alcoholic fatty liver disease: The noninvasive way
por: Gude, Dilip
Publicado: (2011)

Silymarin: An option to treat non-alcoholic fatty liver disease
por: Colica, Carmela, et al.
Publicado: (2017)

Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2018)

Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2021)

Noninvasive Imaging for the Evaluation of Non-Alcoholic Fatty Liver Disease Spectrum
por: Liu, Qianjiao, et al.
Publicado: (2021)

Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes”
por: Jeong, Seogsong, et al.
Publicado: (2023)

Hepatitis C virus infection and atherosclerotic cardiovascular disease: recent knowledge, further insights
por: Patoulias, Dimitrios Ioannis, et al.
Publicado: (2020)

Meckel’s diverticulum complications in three first-degree relatives: time to rethink familial predisposition?
por: Patoulias, Ioannis, et al.
Publicado: (2020)

Multipronged Approach to Assess Risk Factors for Non-alcoholic Fatty Liver Disease
por: Hidrus, Aizuddin, et al.
Publicado: (2022)

Comments on Prevalence of Non-alcoholic Fatty Liver Disease and Its Related Factors in Iran
por: Karimi-Sari, H., et al.
Publicado: (2017)

Do artificial sweeteners increase the risk of non-alcoholic fatty liver disease (NAFLD)?
por: Abbas, Tahany, et al.
Publicado: (2020)

Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease
por: Liu, Dong, et al.
Publicado: (2022)

Diagnosing Periprosthetic Joint Infection: Has the Era of the Biomarker Arrived?
por: Deirmengian, Carl, et al.
Publicado: (2014)

Putting guidelines into practice: has the era of perioperative chemotherapy arrived?
por: Georgiou, Chloe L., et al.
Publicado: (2018)

The Era of Point-of-Care Ultrasound Has Arrived: Are Cardiologists Ready?
por: Huang, Gary S., et al.
Publicado: (2020)

Monotherapy with liraglutide – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019)

Non-alcoholic fatty liver disease and the risk of dementia: A meta-analysis of cohort studies
por: Lu, Li-Yu, et al.
Publicado: (2022)

Safety and efficacy of interleukin-1 antagonists in hospitalized patients with COVID-19
por: Dimosiari, Athina, et al.
Publicado: (2023)

Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease
por: Tian, Feng, et al.
Publicado: (2018)

Efficacy and Clinical Value of Liraglutide for Treatment of Diabetes Mellitus Complicated by Non-Alcoholic Fatty Liver Disease
por: Zhang, Zhongyong, et al.
Publicado: (2018)

Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
por: Luo, Ying, et al.
Publicado: (2019)

Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
por: Yang, Mengying, et al.
Publicado: (2020)

Laparoscopy in Liver Transplantation: The Future has Arrived
por: Lai, Quirino, et al.
Publicado: (2012)

Therapeutic versus prophylactic heparin for thromboprophylaxis in patients with COVID-19: weighing the costs and benefits. A rapid meta-analysis of randomized controlled trials
por: Dimosiari, Athina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8vahhetgnukcp5pmsrafm9o376